NCT06540261Active, not recruitingPhase 1
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
An Open-label, Uncontrolled Study of ONO-7913, ONO-4538 and the Standard of Care FOLFOX in Combination With Bevacizumab or Cetuximab as First-line Treatment in Patients With Unresectable Advanced or Recurrent Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- First submitted
- 1 Aug 2024
- Start date
- 23 Sept 2021
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Diseases
- Colorectal cancer
- NCT number
- NCT06540261
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 65
- From 23 Sept 2021 to the primary completion date, 31 Dec 2027
- 17 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with multiple primary cancers
Other
- Patients with severe complication
Who the study is looking for
- Unresectable advanced or recurrent colorectal cancer
- Life expectancy of at least 3 months
- Patients with ECOG performance status 0 or 1
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chiba Cancer Center Coordinator of this site? Confirm its status | Chiba | Japan | Unknown status |
| National Cancer Center Hospital Coordinator of this site? Confirm its status | Chūōku | Japan | Unknown status |
| Saitama Medical University International Medical Center Coordinator of this site? Confirm its status | Hidaka | Japan | Unknown status |
| Kansai Medical University Hospital Coordinator of this site? Confirm its status | Hirakata | Japan | Unknown status |
| National Cancer Center Hospital East Coordinator of this site? Confirm its status | Kashiwa | Japan | Unknown status |
| St. Marianna University Hospital Coordinator of this site? Confirm its status | Kawasaki | Japan | Unknown status |
| Kobe City Medical Center General Hospital Coordinator of this site? Confirm its status | Kobe | Japan | Unknown status |
| Cancer Institute Hospital of JFCR Coordinator of this site? Confirm its status | Koto-Ku | Japan | Unknown status |
| Kurashiki Central Hospital Coordinator of this site? Confirm its status | Kurashiki | Japan | Unknown status |
| Osaka General Medical Center Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Osaka International Cancer Institute Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| National Hospital Organization Osaka National Hospital Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Hokkaido University Hospital Coordinator of this site? Confirm its status | Sapporo | Japan | Unknown status |
| Saitama Cancer Center Coordinator of this site? Confirm its status | Shinden | Japan | Unknown status |
| Osaka Medical and Pharmaceutical University Hospital Coordinator of this site? Confirm its status | Takatsuki | Japan | Unknown status |
| Fujita Health University Hospital Coordinator of this site? Confirm its status | Toyoake | Japan | Unknown status |
| Kanagawa Cancer Center Coordinator of this site? Confirm its status | Yokohama | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.